drugset / Trial / NCT02791438

A Phase 3 Long-term Study of TAK-536 in Pediatric Patients 6 to Less Than 16 Years With Hypertension

NCT02791438

Phase 3 Completed 27 enrolled Takeda
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety of administration of azilsartan in pediatric patients aged 6 to less than 16 years with hypertension.

Timeline

Start
2016-08-18
Primary completion
2019-06-04
Completion
2019-06-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Azilsartan Unknown 20 mg Oral
Subject Azilsartan Unknown 40 mg Oral